LGMN and neoplasm: Our preclinical studies have shown that LGMN inhibition in combination with anti–PD-1 therapy can inhibit tumor progression, but not cure any tumor-bearing mice (37), suggesting that further efforts are needed to reveal the molecular basis underlying this therapy resistance and develop effective LGMN-targeted/related therapies.